Skip to main content
. Author manuscript; available in PMC: 2019 Jan 30.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2012 Mar 6;15(3):289–295. doi: 10.1038/pcan.2012.7

Table 4.

EPIC questionnaire scores

All patients (n = 26) S-IL-2 (n = 13) M-IL-2 (n = 13) P-value
Mean summary scores (s.d.)
 Urinary 88.3 (11.6) 87.9 (12.7) 88.7 (10.9) 0.97
 Bowel 85.8 (14.0) 82.4 (16.7) 89.1 (10.1) 0.51
 Sexual 41.2 (24.7) 39.9 (22.1) 42.6 (28.0) 0.81
 Hormonal 84.6 (14.2) 83.1 (16.1) 86.1 (12.6) 0.60
Domain-specific subscales
 Urinary Function 92.4 (12.5) 91.4 (12.0) 93.3 (13.4) 0.33
 Bother 84.2 (13.0) 84.3 (14.5) 84.1 (12.0) 0.71
 Incontinence 87.6 (19.1) 87.4 (14.3) 87.8 (23.6) 0.43
 Irritation/obstruction 88.5 (10.1) 88.2 (11.7) 88.7 (8.7) 0.87
Bowel
 Function 86.8 (11.9) 84.3 (13.5) 89.3 (10.1) 0.40
 Bother 84.8 (17.3) 80.5 (21.2) 89.0 (11.7) 0.41
Sexual
 Function 30.1 (24.9) 27.1 (24.8) 32.8 (25.8) 0.55
 Bother 53.5 (32.7) 56.3 (27.8) 50.5 (38.3) 0.62
Hormonal
 Function 83.1 (15.5) 82.7 (17.2) 83.5 (14.3) 0.99
 Bother 86.2 (15.9) 83.6 (16.8) 88.8 (15.2) 0.27

Abbreviations: EPIC, expanded prostate cancer index composite; IL, interleukin; M-IL-2, metronomic dose IL-2; S-IL-2, standard dose IL-2.